HC Wainwright Analysts Increase Earnings Estimates for TVRD

Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Free Report) – HC Wainwright upped their FY2026 EPS estimates for Tvardi Therapeutics in a report released on Friday, November 13th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($2.32) per share for the year, up from their prior forecast of ($2.56). The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2027 earnings at ($1.51) EPS and FY2028 earnings at ($1.56) EPS.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03.

Several other equities analysts also recently commented on the company. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Chardan Capital began coverage on Tvardi Therapeutics in a research report on Tuesday, October 20th. They set a “buy” rating for the company. BTIG Research decreased their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Wall Street Zen cut Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, November 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.40.

Read Our Latest Stock Analysis on Tvardi Therapeutics

Tvardi Therapeutics Stock Performance

TVRD opened at $1.10 on Tuesday. The firm’s fifty day moving average is $1.22 and its 200 day moving average is $2.58. Tvardi Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $5.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $63,000. Finally, GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $34,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

Featured Articles

Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.